Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 2/20 | 0.34 |
| ▸ | CALCRL | Q16602 | 5/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.34 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6803718 | 0.88 | KDM4E (0.35) | CYP3A4CALCRLL3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL6800821 | 0.83 | CALCRL (0.42) | CYP3A4CALCRLL3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL4593241 | 0.78 | KDM4E (0.37) | CALCRLL3MBTL3L3MBTL1MBTD1PARP1 | |
| SCHEMBL4857017 | 0.76 | LRRK2 (0.38) | CYP3A4CYP2D6CYP2C19LRRK2CALCRL | |
| SCHEMBL6798879 | 0.74 | LRRK2 (0.39) | CYP3A4CYP2D6CYP2C19LRRK2L3MBTL3 | |
| SCHEMBL4594198 | 0.73 | PDE3B (0.38) | L3MBTL3L3MBTL1MBTD1PARP1KDM4E | |
| SCHEMBL4722263 | 0.73 | CYP3A4 (0.46) | CYP3A4CYP2D6CYP2C19LRRK2CCR3 | |
| SCHEMBL5661064 | 0.72 | CALCRL (0.42) | CYP3A4CALCRL | |
| SCHEMBL5658553 | 0.72 | CALCRL (0.42) | CYP3A4CALCRL | |
| SCHEMBL4858969 | 0.72 | CALCRL (0.40) | CYP3A4CALCRLL3MBTL3L3MBTL1MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539766-B1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | claimed |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | claimed |
| US-20040063735-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | claimed |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| US-20040063735-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063735-A1 | Calcitonin gene related peptide receptor antagonists | CALCRL, CALCA, CALCR | CYP3A4 3269/4885CYP2D6 3191/4885CYP2C19 1029/4885 |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | CALCRL, CALCA, CALCR | CYP3A4 3269/4885CYP2D6 3191/4885CYP2C19 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.